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Abstract 
Depressive symptoms in subjects at Clinical High Risk for Psychosis (CHR-P) or at first-episode 
psychosis (FEP) are often treated with antidepressants. Our cross-sectional study investigated whether 
brain morphology is altered by antidepressant medication. High-resolution T1-weighted structural MRI 
scans of 33 CHR-P and FEP subjects treated with antidepressants, 102 CHR-P and FEP individuals 
without antidepressant treatment and 55 controls, were automatically segmented using Freesurfer 6.0. 
Linear mixed-effects modelling was applied to assess the differences in subcortical volume, surface area 
and cortical thickness in treated, non-treated and healthy subjects, taking into account converted dosages 
of antidepressants. Increasing antidepressant dose was associated with larger volume of the pallidum 
and the putamen, and larger surface of the left inferior temporal gyrus. In a pilot subsample of separately 
studied subjects of known genomic risk loci, we found that in the right postcentral gyrus, the left 
paracentral lobule and the precentral gyrus antidepressant dose-associated surface increase depended on 
polygenic schizophrenia-related-risk score. As the reported regions are linked to the symptoms of 
psychosis, our findings reflect the possible beneficial effects of antidepressant treatment on an emerging 
psychosis. 
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Introduction 
Appearance of psychosis is considered to be the driving force of multiple debilitating mental 
disorders, including schizophrenia1,2, which affects 0.7% of the world population3. Psychosis presents 
itself in a diffuse temporal and phenomenological range of symptoms, of disparate severity and 
persistence4,5. Before their assignation to the first episode of psychosis (FEP) group, subjects at risk 
belong to a heterogeneous group of Clinical High Risk for Psychosis (CHR-P), characterised by 
attenuated psychotic symptoms, brief limited intermittent psychotic symptoms, genetic risk or 
schizotypal traits and a decline in social and occupational functioning6-9. The disorder usually manifests 
itself in early adulthood and the active search for reliable transition markers continues as around 20% of 
the CHR-P undergo transition to FEP during the first two years10.  
Multiple findings indicate that CHR-P and FEP show similar functional11 and structural brain 
abnormalities9,10,12-13, but it is unclear to what extent they reflect genetics, general distress, medication 
effects or are unique features associated with the at risk stage of the disorder. The psychosis 
vulnerability seems associated with progressive nonlinear morphological changes, to which the 
pleiotropic genetic factors, the medication and non-genetic factors may contribute14-16. CHR-P subjects 
show structural abnormalities in frontal, cingular and temporal cortices, insular regions, temporal gyrus 
and some of these changes may be predictive of later transition to psychosis16-24. 
CHR-P and FEP individuals often suffer from comorbid depressive and anxiety symptoms25,26 that 
can precede27 or accompany the onset of attenuated positive psychotic symptoms.9,28 These features are 
the main reason for seeking help at specialized services29 and the occurrence of these is significantly 
associated with decreased likelihood of remission from CHR-P. 30,31 Antipsychotic treatment usually 
begins after the first episode of psychosis and non-random comparative studies of antidepressants and 
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antipsychotics indicate that antidepressants might be a beneficial effective treatment for preventing 
psychosis in CHR-P individuals.32-34 
Currently CHR-P and FEP subjects are occasionally treated with antidepressants if they present 
depressive symptoms35, but the effect of antidepressant medication on brain morphology has, to the best 
of our knowledge, rarely been explored in the CHR-P and FEP cohorts. 
The morphological reduction in major depression was observed in the prefrontal, temporal and 
parieto-occipital regions, basal ganglia, inferior/middle temporal gyri, hippocampus, and the 
cerebellum.36-39 It was shown for depression that antidepressant treatment was connected to enlargement 
of the frontal cortex, middle frontal gyrus, anterior cingulate, and hippocampus.40-44 It is linked to an 
increase in grey matter volume45, it influences brain connectivity 46, and it modulates synaptogenesis, 
neurogenesis and dendritic arborisation in animal models and in the human hippocampus 47-50. A recent 
study of affective psychoses51 did not detect long-term antidepressant effect on any brain regions, 
although – like in other studies – only general presence or absence of antidepressants was used as a 
predictor. 
As the goal of ongoing international research efforts is to establish reliable brain markers to 
complement clinical features for the prediction of psychosis onset, it is crucial to disentangle disease and 
medication effects on brain morphology in CHR-P and FEP individuals. Therefore, the aim of our 
investigation was to study whether morphological features such as cortical thickness, surface area and 
subcortical volume were altered after administration of antidepressant medication in CHR-P and FEP 
subjects. The focus on subcortical volumes is based on previous studies in FEP14,68,94 and UHR95,96 
patient showing alterations in these cohorts relative to healthy volunteers. Cortical thickness and surface 
area were further considered because such surface-based measures are probably more sensitive to detect 
brain alterations in early phases of psychosis93. 
5 
 
As there are only a few studies showing an impact of antidepressant medication on volume, 
thickness and surface 26,51 in CHR-P and FEP, we investigated the influence of antidepressant dose on 
the whole-brain. As shown in the cited literature, antidepressant effect is often linked to modifications in 
the frontal regions and in hippocampus, and we expected to register the structural effects primarily in 
these regions. 
While in CHR-P and FEP the transition risk and morphology52 are co-modulated by genetics, our 
additional aim was to identify if there is an impact of combined cumulative estimate of known genomic 
risk loci (polygenic schizophrenia-related risk scores or PSRS53) on the effect of antidepressants on 
brain morphology in CHR-P and FEP, as subjects with high/low genetic risk might have different 
medication effect because of the different illness endophenotypes or a genetic overlap between 
pathogenesis and drug action.54 Although a recent study 55 did not find evidence of genetic overlap 
between schizophrenia risk and subcortical volume, several studies have already reported an association 
of a PSRS with brain volume.56-58 Our focus on analysing the interaction of PSRS and antidepressant 
medication on thickness, surface and subcortical volume is novel in the context of previous studies and 
we hypothesise that the antidepressant medication effect on brain morphology may depend on the 
genetic predisposition for psychosis. 
 
Results 
Demographics and clinical characteristics 
Samples with and without genetics data (Table 1) exhibited no significant differences (p>0.05) in 
age, handedness or IQ. SANS did not differ between CHR-P and FEP. There were significant 
differences between groups in sex distribution in the full sample (p<0.001), but not in the PSRS 
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subsample (p>0.05), and in the years of education distribution in the full sample (p<0.001), but not in 
the PSRS subsample (p>0.05). In both samples, there was a significant between-group difference in 
overall BPRS (both samples p<0.001), cannabis consumption (p=0.007, p<0.001) and GAF (both 
samples p<0.001). 
 
Insert Table 1 here 
Morphometric differences 
We proceed reporting effects that survived FDR correction with a significance threshold of p<0.05 
followed by exploratory findings that survived an uncorrected threshold of p<0.01. Table 2 shows a 
summary of the significant LME results for antidepressants dose effects on brain regions in the whole 
sample; Table 3 shows the regions for which an interaction between PSRS and medication was required 
to explain variations in surface or volume.  
 
Insert Table 2 and Table 3 here 
 
Subcortical volume 
We detected a significant main effect of antidepressant dosage on the putamen (β=0.0166, 
s.e.=0.0053, p=0.0019) and the pallidum (β=0.0157, s.e.=0.0049, p=0.0016), both survived FDR 
correction. A Tukey post-hoc test revealed an enlargement trend in antidepressant-treated CHR-P and 
FEP subjects’ subcortical volume. The left pallidum in the group of antidepressant-treated CHR-P and 
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FEP subjects was enlarged compared to healthy controls (p=0.04). The putamen was enlarged in 
antidepressant-treated CHR-P and FEP subjects compared to the non-treated CHR-P and FEP subjects 
(left p=0.05, right p>0.05) and healthy controls (left p=0.003, right p=0.006).  
A group-wise Tukey post-hoc test showed that the medicated CHR-P group exhibited significant 
enlargement in the left putamen (p=0.02) compared to unmedicated CHR-P and the medicated FEP 
group exhibited enlargement of the right putamen (p=0.02) and bilateral pallidum (left p=0.006, right 
p=0.036) compared to the unmedicated FEP. 
We also found the main effect of antidepressant dosage on nucleus accumbens (NAcc) (β=0.0152, 
s.e.=0.0051, p=0.0033), but it did not survive the FDR correction. A Tukey post-hoc test revealed that 
left NAcc was enlarged in the group of antidepressant-treated CHR-P and FEP subjects compared to the 
non-treated CHR-P and FEP subjects (p=0.02). There was a trend to enlargement in left NAcc in 
medicated FEP group (p=0.03) - compared to the unmedicated group. 
We found no significant interaction effects of antidepressant dosage and PSRS for subcortical 
structure volume. 
Surface area 
We detected a significant main effect of antidepressant dosage on the surface of the inferior 
temporal gyrus (β=0.0154, s.e.=0.0048, p=0.0014, survived FDR). For the surface of the left inferior 
temporal gyrus the Tukey post-hoc test revealed the significant enlargement (p=0.01) in antidepressant-
treated CHR-P and FEP subjects compared to non-treated CHR-P and FEP subjects. 
We detected a significant main effect of antidepressant dosage on the surfaces of the fusiform 
gyrus (β=0.0134, s.e.=0.0049, p=0.0067), the middle temporal gyrus (MTG) (β=0.0151, s.e.=0.0054, 
8 
 
p=0.0055), and the inferior parietal lobule (β=0.0152, s.e.=0.0053, p=0.005) and they did not survive 
the FDR correction threshold. 
The Tukey post-hoc test revealed the significant enlargements in antidepressant-treated CHR-P 
and FEP subjects compared to non-treated CHR-P and FEP subjects in the surface of the left fusiform 
gyrus (p=0.01) and the right inferior parietal lobule (p=0.048). 
A group-wise Tukey post-hoc test registered the significant (p=0.01) increase in the surface of the 
medicated FEP group compared to the non-medicated FEP group in a right inferior parietal lobule and 
the non significant (p>0.05) trend to increase in the left fusiform gyrus, the left inferior temporal gyrus, 
the left inferior parietal lobule. 
We found a significant interaction effect of antidepressant dosage and PSRS (Table 3) on the 
surface of the precentral gyrus (p=0.0023), the postcentral gyrus (p=0.0028), the paracentral lobule 
(p=0.0014) and the lateral orbitofrontal cortex (p=0.0095). All interactions except in the lateral 
orbitofrontal cortex survived the FDR correction in 2 groups LME. 
Statistical comparison of the slopes of the LME lines (Figures 1-4) by a Tukey post-hoc test 
showed that there was a significant increase in the surface of the bilateral precentral gyrus (left and 
right p=0.05; Fig.1), right postcentral gyrus (p=0.004; Fig.2) and left paracentral lobule (p=0.04; 
Fig.3) and a non-significant increase trend in the lateral orbitofrontal cortex (p>0.05; Fig.4) in 
antidepressant-treated CHR-P and FEP subjects with increasing PSRS and current dose of 
antidepressants, but a slight decrease in non-treated CHR-P and FEP subjects.  
 
Insert Figures 1-4 here 
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Cortical thickness 
We found no significant main effects of antidepressant dosage on the cortical thickness of the 
analysed regions nor an interaction effect between antidepressant dosage and PSRS. 
LR tests 
The LR tests (Tables S4-S5) showed that the difference between the model pairs were significant 
(p<0.01) for all models reported in Tables 2-3, on the supposition that the antidepressant medication 
effect in the full sample and the interactions between PSRS and medication in the subsample were 
significant to explain variation in the data. The same test with 2 groups (CHR-P and FEP) excluding 
healthy controls confirmed our results for all models. 
Correlation analysis 
The correlation analysis between the surface and volume of brain regions and the BPRS, SANS 
and GAF in the full sample and in the PSRS subsample (Tables S2-S3) showed the negative correlations 
(p<0.05 uncorrected) in combined CHR-P and FEP subjects for left fusiform gyrus surface and BPRS-
activation symptom subscale (r=-0.207), left inferior temporal gyrus surface and BPRS (r=-0.251), 
BPRS-activation (r=-0.22) and BPRS-positive (r=-0.226), left middle temporal gyrus surface with 
BPRS (r=-0.232) and BPRS-positive (r=-0.235), left lateral OFC surface with BPRS (r=-0.309), and 
with SANS  (r=-0.283), left paracentral lobule surface and SANS  (r=-0.274); right inferior temporal 
gyrus surface with BPRS-affective (r=-0.176 ), right MTG surface with BPRS-activation (r=-0.199), 
right lateral OFC surface with BPRS (r=-0.265), BPRS-positive (r=-0.335) and with GAF (r=0.396), 
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right precentral gyrus surface with BPRS-affective (r=-0.327). The left pallidum volume was positively 
correlated with BPRS-negative subscale (r=0.238) and with SANS (r=0.223). 
Discussion 
In an analysis of automatically segmented brain regions in CHR-P, FEP and healthy controls, we 
found a significant (FDR p<0.05) main effect of current antidepressant dose on the volume of the 
pallidum and the putamen and surface of the inferior temporal gyrus. Furthermore, we found (FDR 
p<0.05) that the surface of the postcentral gyrus, the paracentral lobule and the precentral gyrus can be 
linked to an interaction between antidepressants dosage and genomic risk score. 
The volumes of the bilateral putamen and the left pallidum were enlarged in antidepressant-
treated CHR-P and FEP compared to the untreated cohort and healthy controls. Diagnosis-related 
increases in the volume of pallidum and the putamen have been previously reported for schizophrenia 
and FEP patients.52,66,67 Putamen and pallidum volume have been identified as predictors of positive 
symptoms and the duration of illness66,68 and it was shown that putamen lesions may lead to psychosis.69 
Moreover, the basal ganglia system has been associated with the dopaminergic hypothesis of 
schizophrenia.2 
We found a significant main effect of antidepressant dose on the surface of the inferior temporal 
gyrus. In particular, the antidepressant-treated CHR-P and FEP subjects exhibited enlarged surface of 
the left inferior temporal gyrus compared to the non-treated CHR-P and FEP subjects. In patients with 
psychosis a decreased volume70-74 and surface area97 in the inferior temporal gyrus was demonstrated. 
Therefore, our finding suggests that antidepressant treatment might increase surface area of the inferior 
temporal gyrus in early stages of psychosis.   
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In the subsample with calculated PSRS, we found an interaction effect between antidepressant 
dose and PSRS on the surface of the precentral and the postcentral gyri, and the paracentral lobule. 
With the rise in both antidepressant dosage and PSRS, the bilateral precentral gyrus, the right 
postcentral gyrus and the left paracentral lobule increased in surface - compared to non-treated CHR-P 
and FEP subjects, where a decreasing trend appeared. 
Morphological and functional changes in these regions have been previously associated with 
psychosis: reduced surface area in the right postcentral gyrus have been reported in 22q11DS subjects98 
and patients with schizophrenia revealed significant reduction in surface area in frontal and parietal 
regions99; the displacement76, abnormal activation77 and the reduction78,79 of the postcentral gyrus are 
characteristic for psychosis. 
The regions where the increase in PSRS is linked to the surface increase due to antidepressant 
treatment are connected to important clinical symptoms. The precentral gyrus has been associated with 
verbal hallucinations80, neurocognitive deficits and attentional deficits.81 Connectivity changes in the 
postcentral gyrus with the dorsolateral prefrontal cortex are linked to the improvement in affective 
psychotic symptoms.82 
According to our findings, one could suggest that antidepressant medication might have a stronger 
influence on surfaces than thicknesses. Their relation is contradictory, as there is evidence that they’re 
negatively correlated83, but also that they’re genetically unrelated and develop independently.84 This is 
in agreement with our finding that only surface but not thickness shows an interaction between 
antidepressants and PSRS. So the effect of antidepressants might be genetically determined and only 
evident for surfaces. Future research is warranted whether the effect of antidepressants in FEP/CHR-P is 
specific for surfaces and whether it is determined by genetic predisposition. 
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The overall improvements in CHR-P and schizophrenia after antidepressant treatment reported in 
the literature are quite inconsistent.85,86 According to the study of remission from major depression87, 
remitters show increase over time and nonremitters show decrease in volume and thickness of cortical 
and subcortical structures. 
The relationship between antidepressant dosage and morphology identified in our study should be 
further examined to determine whether antidepressants can efficiently alleviate symptoms and which 
dose is required; some efforts are already ongoing.88 Thus, determination of the dosage, start of 
prescription and combination with other drugs might be improved in subjects with emerging psychosis. 
In further studies we consider using the duration of antidepressant admission because we cannot 
exclude a possibility that those receiving antidepressants may represent a different subpopulation. 
The evidence of antidepressant effects on the morphophysiology of regions that have a possible 
link to clinical symptoms may provide a scientific rationale to support the notion that earlier 
antidepressant prescription for CHR-P patients could improve their clinical outcomes.34 As the regional 
enlargements are negatively correlated to symptoms, the interactions between PSRS and antidepressant 
dose found in our pilot study of the PSRS subsample might also be of clinical interest as we could 
speculatively propose that subjects with higher PSRS may benefit more from antidepressant treatment in 
order to reduce early symptoms and to limit the morphophysiological side effects. Thus, the 
translational significance of the findings is that these associations may influence the clinical choice of 
optimal medication in CHR-P and FEP subjects. 
Our study had some limitations. Differences in cannabis consumption among groups may also 
have been influenced our findings, although the effect of cannabis on morphological brain measures in 
healthy volunteers and psychotic patients is inconclusive89-92. It was not possible to calculate the 
cumulative lifetime treatment dose of antidepressants due to gaps in medical records. Nevertheless, 
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further studies should include the lifetime dose, as mean dose provides incomplete information in cross-
sectional paradigms. The mean antidepressant dose used in the clinic is relatively low and due to the 
presence of agents with a mixed range of pharmacological action and the limited sample size, we were 
unable to differentiate groups based on antidepressant types. Our sample size did not allow a meaningful 
statistical subanalysis to differentiate between the different clinical high-risk subgroups APS, BLIPS 
and GRD.9 Given that their risk of developing psychosis is different13, future studies are advised to 
stratify their findings across these subgroups. The number of tests was large due to the multitude of 
regions possibly implicated in response to antidepressant treatment. The current inferences about the 
PSRS effect are speculative because of the modest sample, and the future studies should investigate 
different morphophysiological effects in low and high PSRS cohort, as more genetic data should be 
collected. The effect of disease stage should also be included in the larger sample. The underlying 
biological mechanism of these modifications needs to be further investigated. 
In sum, to our knowledge, we have demonstrated for the first time the association of the converted 
antidepressant dosage on morphological brain changes and the interaction between antidepressants 
dosage and genomic risk score in CHR-P and FEP subjects. As most of the reported regions were shown 
as linked to the clinical symptoms of psychosis, our findings may contribute to explanations of the 
suggested beneficial effects of antidepressant treatment in this population. 
 
Methods 
Participants 
We use the cross-sectional data of 142 patients (72 FEP, 70 CHR-P) and 55 controls recruited in 
the FePsy (early detection of psychosis) study (see full Participants, Screening and Genotyping 
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description in Supplementary materials). The PSRS data was obtained for a subsample of 61 patients: 
32 FEP and 29 CHR-P, as well as for 14 controls. The data overlaps (n=72) with our previous studies.52 
All participants provided written informed consent and received compensation for participating. 
The studies had permission from the ethics committee beider Basel (EKBB). All methods were 
performed in accordance with the relevant guidelines and regulations. 
Screening 
The participants were assessed using the Basel Screening Instrument for Psychosis (BSIP).59 
Subjects selected for the study by screening subsequently underwent an entry examination, which 
included the Brief Psychiatric Rating Scale (BPRS), Scale for the Assessment of Negative Symptoms 
(SANS), and a neuropsychological test battery. Inclusion criteria in the CHR-P group required a) 
attenuated symptoms or b) brief limited intermittent psychotic symptoms and genetic risk or schizotypal 
features, coupled with functional deterioration.60 The transition to FEP required the occurrence of at 
least one positive psychotic symptom several times a week for a continuous period of time. 
Exclusion criteria 
Age below 18 years, insufficient knowledge of German, IQ<70, previous episode of psychosis 
treated with major tranquillisers for >3 weeks, a psychosis due to organic reasons or substance abuse, or 
psychotic symptomatology within a clearly diagnosed affective psychosis or borderline personality 
disorder. 
Medication 
The current mean converted antidepressants dose was 28.14mg Fluoxetine equivalent61 in the full 
sample and 29.53mg for the PSRS subsample. The assignment of antidepressant treatment in our sample 
was non-random i.e. according to clinical needs and consisted of escitalopram (n=10), fluoxetine (n=4), 
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citalopram (n=2), paroxetine (n=2), sertraline (n=2); venlafaxine (n=4); mirtazapine (n=5); trazodone 
(n=2) and bupropion (n=1). The PSRS subsample included escitalopram (n=3), fluoxetine (n=4), 
sertraline (n=1); venlafaxine (n=4); mirtazapine (n=2) and trazodone (n=2) treatment. N=38 subjects 
from the full sample and n=12 subjects from PSRS subsample were medicated with second-generation 
antipsychotics (SGA). Current antipsychotic dose was converted into chlorpromazine (CPZ) 
equivalents.62 The mean CPZ equivalents (s.d.) were 214.5 (271.1). N=9 subjects were taking both SGA 
and antidepressants. No healthy control was medicated with antidepressants or SGA. N=36 subjects 
from the full sample and n=18 subjects from PSRS subsample consumed cannabis. 
Genotyping and PSRS calculation 
DNA in the PSRS subsample was extracted from whole-blood samples. PSRS was calculated by 
taking linkage disequilibrium-pruned loci.53,63 A total of 87 SNPs that could be mapped to one of the top 
SNPs of the 108 loci associated with schizophrenia and that survived quality control were used to 
calculate the PSRS. The number of risk alleles per person was weighted for each SNP by the logarithm 
of its odds ratio as reported in the PGC SZ data set and summed across SNPs.64 The PSRS was then 
corrected for the first 20 genotypic principal components (PCs) and the number of SNPs used to 
calculate the PSRS by using the z-transformed residuals of a linear regression. 
Acquisition and analysis of MRI data 
We obtained structural MRI scans within an average of 25 days after entry into our early detection 
service, using a 3T MR imaging scanner (Siemens Magnetom Verio, Siemens Healthcare, Erlangen, 
Germany) with a 12-channel phased-array radio frequency head coil. For structural images, a 3D T1-
weighted magnetisation-prepared rapid gradient echo sequence was used with the following parameters: 
inversion time: 1000 ms, flip angle=8 degrees, repetition time=2 s, echo time=3.37 ms, field of 
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view=25.6 cm, acquisition matrix=256×256×176, resulting in 176 contiguous sagittal slices with 
1×1×1 mm3 isotropic spatial resolution. All scans were screened for gross radiological abnormalities by 
an experienced neuroradiologist. N=16 subjects were excluded due to erroneous MR scans (2 FEP, 11 
CHR-P and 3 HC). 
MR images were processed through Freesurfer 6.0 automated segmentation pipeline 
(https://surfer.nmr.mgh.harvard.edu/fswiki/recon-all/). A total of 41 parcellated brain regions were 
obtained using the recon-all fully-automated directive workflow with the default Deskian-Killiany atlas. 
The workflow included motion correction, brain extraction, Talairach transformation, segmentation of 
cortical and subcortical structures, intensity normalization, gray matter-white matter boundary 
tessellation, and topology correction. Results were visually inspected and statistically evaluated for 
outliers following standardized ENIGMA protocols for cortical and subcortical structures 
(http://enigma.ini.usc.edu/protocols/imaging-protocols/) and outlier removal was performed with the 
code provided by the ENIGMA Consortium (http://enigma.ini.usc.edu/protocols/imaging-protocols/) 
and continued if the regional value was not in a range of ± 3.5 standard deviations. Subsequently, 
cortical thickness, surface area and subcortical volume of all 41 brain areas were normalised with 
respect to intracranial volume and centred. 
After the quality check of the main study population (Table 1), the full sample, with and without 
PSRS data, consisted of combined 22 CHR-P and 11 FEP subjects treated with antidepressants, 45 
CHR-P and 57 FEP individuals without antidepressant treatment and 55 healthy controls. 
Statistical analysis 
The R software v.3.4.0 with packages `lmertest`v.2.0.36, `effects`v.4.0, `emmeans`v.0.9.1, `car` 
v.2.1.6 was used for statistical, group-related descriptive analysis. Adequate statistical tests (ANOVA, 
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logistic regression, chi-squared test or t-test) were applied to examine group effects on the following 
variables of interest: age, sex, handedness, years of education, IQ, BPRS, PSRS, cannabis use, 
antipsychotics and antidepressants (Table 1 and Table S1). Additionally the Pearson correlation 
coefficient was calculated for BPRS65, SANS and GAF score correlated with the anatomical data of 
each separate region. Current mean antidepressant dose was converted into fluoxetine equivalents. 
To investigate the medication effect on brain morphology (cortical thickness, surface area and 
subcortical volume), we constructed several linear mixed effect models (LME) that contained current 
converted antidepressant medication dose, diagnosis, sex, age, hemisphere, and interaction between 
current daily medication dose and hemisphere as fixed effects and intercept for every subject as random 
effect for each brain region. To test the hypothesis that antidepressant medication effects on cortical and 
subcortical structures varies in subjects with different genetic predisposition for psychosis, we 
constructed LME that included current converted medication dose of antidepressants, corrected PSRS 
score, interaction between daily medication dose and PSRS, diagnosis, sex, age, hemisphere and 
interaction between medication, PSRS and hemisphere as fixed effects and intercept for subject as 
random effect. LMEs were summarized by an ANOVA type 2 for medication effects alone (Table 2) 
and by an ANOVA type 3 for the interaction effects between medication and PSRS score in the PSRS 
subsample (Table 3). 
Analyses for each region were followed by Tukey’s HSD post-hoc test uncontrolled for 41 brain 
regions studied (Tables S6-S8, p<0.05 was considered significant). Likelihood ratio (LR) tests were 
performed for all of the constructed LME in the corresponding brain regions (Tables S4-S5). Reduced 
models did not contain [medication] and [medication*hemisphere] effects in the full sample and did not 
contain the interactions [PSRS*medication] and [PSRS*medication*hemisphere] in the PSRS 
subsample.     
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Figure legends 
Figure 1: LME for significant interaction between antidepressants dosage and genomic risk score 
for the surface of the precentral gyrus 
Figure 2: LME for significant interaction between antidepressants dosage and genomic risk score 
for the surface of the postcentral gyrus  
Figure 3: LME for significant interaction between antidepressants dosage and genomic risk score 
for the surface of the paracentral lobule 
Figure 4: LME for significant interaction between antidepressants dosage and genomic risk score 
for the surface of the lateral orbitofrontal cortex 
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Tables 
Combined CHR-P and FEP 
without antidepressants (NT)
Combined CHR-P and FEP 
treated with antidepressants (T)
HC Statistics P-value Post-hoc
43 15 14
102 33 55
‘23/10 ‘12/3 ‘6/8 X2 = 4.43 (2) 0.11
‘71/31 ‘23/10 ‘22/33 X2 = 14.2 (2) 0.0008
24.58  (6) 26.87  (7.23) 26.4 (2.75) Anova  F value= 1 (2) 0.37
25.29  (6.13) 26.55  (6.56) 25.93 (4.68) Anova  F value= 0.64 (2) 0.53
‘6/37 ‘2/13 ‘1/13 X2 = 0.516 (2) 0.77
‘10/91 ‘2/31 ‘3/35 X2 = 0.306 (2) 0.86
13.58  (2.6) 14.33  (3.36) 16.1 (3.4) Anova  F value=  2.08 (2) 0.13
13.23  (2.6) 14.24  (3.23) 15.32 (2.76) Anova  F value = 8.22 (2) 0.0004 HC > NT
108.70 (14.53) 115.33 (19.18) 117.6 (11.2) Anova  F value = 1.99 (2) 0.15
108.44 (15.02) 113.79 (16.15) 116.5 (11.43) Anova  F value = 2.87 (2) 0.061
45.46 (15.17) 41 (10.91) 24.4 (0.91) Anova  F value = 14.4 (2) <0.0001 HC < T , NT
42.63 (13.57) 40.67  (9.09) 24.16 (0.57) Anova  F value = 56.1 (2) <0.0001 HC < T , NT
6.54 (3.44) 7.07 (2.53) 3.20 (0.56) Anova  F value = 8.44 (2) 0.0006 HC < T , NT
6.02 (2.90) 7.03 (2.61)  3.09 (0.35) Anova  F value = 36.6 (2) <0.0001 HC < T , NT
6.15 (3.07) 6.21 (2.64) 3 (0) Anova  F value = 7.93 (2) 0.0008 HC < T , NT
5.25 (2.81) 6.23 (2.66) 3 (0) Anova  F value = 24.3 (2) <0.0001 HC < T , NT
8.56 (4.52) 7.21 (4.37) 3 (0) Anova  F value = 9.95 (2) 0.0002 HC < T , NT
8.07 (4.52) 6.80 (3.63) 3 (0) Anova  F value = 34.7 (2) <0.0001 HC < T , NT
3.85 (1.87) 3 (0.78) 3 (0) Anova  F value = 2.65 (2) 0.079
3.85 (1.92) 3.23 (0.97) 3 (0) Anova  F value = 6.43 (2) 0.002 HC < NT
17.61 (14.38) 18.71 (12.53) t = 1.4 0.2
14.10 (12.64) 17.70 (12.42) t = 0.27 0.8
64.81 (17.32) 63.93 (13.14) 89.3 (4.9) Anova  F value = 15.8 (2) <0.0001 HC > T , NT
65.11 (15.96) 60.81 (13.16) 91.9 (4.5) Anova  F value =  89 (2) <0.0001 HC > T , NT
35/8 11/4 X2 = 0.086 (1) 0.08
73/29 24/9 X2 ~ 0 (1) ~1
34/9/0 6/8/1 13/1/0 X2 = 9.95 (2) 0.0069
80/21/1 17/13/3 52/2/1 X2 = 20.9 (2) <0.0001
0.02 (1) 0.02 (1.05) Anova  F value = 0.09 (2) 0.92
NA
Table 1: Demographics and clinical characteristics
Full sample
Number of subjects
PSRS subsample
Full sample
Sex M/F 
PSRS subsample
Full sample
Mean age in years (s.d.)
PSRS subsample
Full sample
Handedness left/non-left
PSRS subsample
Full sample
Years of education (s.d.)
PSRS subsample
Full sample
IQ (s.d.)
PSRS subsample
Full sample
BPRS (s.d.)
PSRS subsample
Full sample
BPRS affective (s.d.)
PSRS subsample
Full sample
BPRS negative (s.d.)
PSRS subsample
Full sample
BPRS positive (s.d.)
PSRS subsample
Full sample
BPRS activation (s.d.)
PSRS subsample
sd: standard deviation ; T: treated by antidepressants ; NT: not treated by antidepressants ; NA: no data ; all post-hoc analyses correspond to p<0.05
Normalized PSRS  (s.d.)
PSRS subsample
SANS (s.d.)
PSRS subsample
Full sample
GAF (s.d.)
PSRS subsample
Full sample
Antipsychotics no/yes
PSRS subsample
Full sample
Cannabis no/yes/NA
Full sample
PSRS subsample
NA
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F P-value F P-value F P-value F P-value F P-value F P-value F P-value
Age 0.0051 0.9434 0.0053 0.942 0.8376 0.3613 2.3312 0.1285 7.1333 0.0082*** 2.733 0.1 0.724 0.3959
Antidepressants dose 7.5094 0.0067* 10.2445 0.0016*** 8.0283 0.0051* 10.4924 0.0014*** 7.8861 0.0055* 8.8841 0.0033* 9.9351 0.0019***
Antidepressants dose x hemisphere 0.9359 0.3346 0.1058 0.7454 1.9489 0.1644 1.0673 0.3029 0.0466 0.8294 0.2529 0.6156 0.5055 0.478
Diagnosis 3.7807 0.0246 2.2706 0.1061 0.0022 0.9978 5.1127 0.0069* 0.1802 0.8352 2.2488 0.1084 2.4659 0.0877
Hemisphere 0.017 0.8965 0.4368 0.5095 0.0481 0.8266 0.0013 0.9716 0.67 0.4142 0.0015 0.9697 0.0908 0.7635
Sex 5.1986 0.0237 9.8685 0.002*** 1.1203 0.2912 4.0807 0.0448 1.1284 0.2895 1.0903 0.2978 6.8627 0.0095***
F P-value F P-value F P-value F P-value F P-value F P-value F P-value
Age 1.2241 0.2706 0.4671 0.4956 0.0062 0.9376 0.085 0.7711 4.1447 0.0438 1.6135 0.2063 0.1921 0.6619
Antidepressants dose 7.0187 0.0091* 10.8786 0.0013*** 7.2448 0.008* 9.3836 0.0027* 7.2142 0.0082* 8.0509 0.0053* 11.2135 0.0011***
Antidepressants dose x hemisphere 0.9548 0.3303 0.3089 0.5793 2.1568 0.1443 1.378 0.2426 0.1566 0.693 0.0884 0.7667 0.4115 0.5223
Diagnosis 3.2054 0.0757 4.2515 0.0412 0.0094 0.9228 9.2156 0.0029* 0.1988 0.6564 1.3446 0.2484 2.4243 0.1219
Hemisphere 0.0104 0.9188 0.0043 0.9478 0.1529 0.6964 0.0797 0.7781 1.0156 0.3156 0.1842 0.6685 0.0027 0.9588
Sex 4.3878 0.0381 13.6249 0.0003*** 3.3 0.0716 3.1462 0.0785 0.4173 0.5195 1.3707 0.2438 12.7727 0.0005***
Putamen vol. 
*P-value<0.01, ***survived correction for FDR with P-value<0.05, GP: Globus Pallidus, MTG: medial temporal gyrus, NAcc: nucleus accumbens, gyr.: gyrus, lob.: lobule, surf: surface, vol.: volume
Fusiform gyr. surf. GP vol. 
Inferior parietal lob. 
surf. 
Inferior temporal gyr. 
surf. 
MTG surf. NAcc vol. 
FEP, CHR-P, HC
FEP, CHR-P
Table 2. Summarized linear mixed effects models for antidepressants
Fusiform gyr. surf. GP vol. 
Inferior parietal lob. 
surf. 
Inferior temporal gyr. 
surf. 
MTG surf. Putamen vol. NAcc vol. 
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F P-value F P-value F P-value F P-value
Age 4.6873 0.0341 0.869 0.3548 3.3973 0.07 0.517 0.4748
ADeq x PSRS 7.0471 0.0095* 10.8924 0.0014* 9.3919 0.0028* 9.848 0.0023*
ADeq x PSRS x hemisphere 4.4517 0.0384 2.5105 0.1177 0.2056 0.6517 0.0081 0.9286
Antidepressants dose 2.9211 0.0923 3.5752 0.0632 4.08 0.0477 4.7202 0.0335
Diagnosis 0.0452 0.9559 0.5532 0.5778 0.2971 0.744 0.5067 0.6049
Hemisphere 0.1085 0.7428 0.2191 0.6412 0.0045 0.9466 0.1297 0.7198
PSRS 0.0187 0.8917 0.1503 0.6996 0.5883 0.4459 0.474 0.4937
Sex 1.1951 0.2784 0.0795 0.7788 0.0593 0.8085 0 0.9999
F P-value F P-value F P-value F P-value
Age 3.8094 0.0565 0.6519 0.4232 4.1523 0.0468 0.4273 0.5163
ADeq x PSRS 7.0548 0.0098* 10.3231 0.002*** 11.4315 0.0011*** 10.5822 0.0017***
ADeq x PSRS x hemisphere 4.2635 0.0436 2.4821 0.121 0.1726 0.6795 0.0039 0.9504
Antidepressants dose 2.8239 0.099 3.0493 0.0869 4.1067 0.048 4.1415 0.0471
Diagnosis 0.0009 0.9765 0.6933 0.4089 0.0878 0.7681 0.5546 0.4599
Hemisphere 0.0433 0.8359 0.1112 0.7401 0.0638 0.8015 0.0194 0.8896
PSRS 0.1816 0.6718 0.2093 0.6493 1.8401 0.1808 1.5295 0.2219
Sex 0.6018 0.4415 0.0055 0.9412 1.0283 0.3154 0.1753 0.6772
Table 3: Summarized linear mixed effects models for antidepressants x PSRS interaction in the PSRS subsample
FEP, CHR-P, HC with PSRS
FEP and CHR-P with PSRS
*P-value<0.01, ***survived correction for FDR with P-value<0.05, OFC: orbito-frontal cortex, lat.: lateral, surf: surface, vol.: volume, ADeq: antidepressant 
medication fluoxetine equivalents, PSRS: polygenic schizophrenia risk score
Lat. OFC surf. Paracentral lob. surf. Postcentral gyr. surf. Precentral gyr. surf. 
Lat. OFC surf. Paracentral lob. surf. Postcentral gyr. surf. Precentral gyr. surf. 
 
 
 
 




